Inactive

The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the Corona Virus Disease 2019 (COVID-19) pandemic. The Air Force Senior Acqu... The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the Corona Virus Disease 2019 (COVID-19) pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense for Defense Assisted Acquisition Cell (DA2) and (ii) to collect and consolidate funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE’s) LOE’s: (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort. As the U.S. Government response to the COVID-19 pandemic has evolved, the DA2 mission has also evolved to include the replenishment of the Strategic National Stockpile (SNS) and expand and preserve the domestic manufacture of key medical personnel protective equipment (PPE) items, screening and diagnostics instruments and supplies, finished drugs and active pharmaceutical ingredients and the associated finishing and delivery capabilities. The Department of the Air Force Acquisition Task Force combined with the DA2, will lead rapid solicitation and execution of contracts in support of the DA2 mission. This CSO announcement anticipates soliciting solution briefs through separate and periodically published Areas of Interest (AOI) to meet Department of Health and Human Services (HHS) COVID-19 response priorities, with an emphasis on SNS goals that achieve (1) more coverage to ensure sufficient inventory of major PPE, equipment and drugs associated with COVID-like pandemics, (2) greater insight to forecast requirements, (3) use various inventory management strategies and improved visibility into supply and demand, and (4) enhance manufacturing capacity to reduce dependency on foreign sources of supply. The CSO is a streamlined acquisition process that seeks to reduce acquisition timelines and acquire new, innovative solutions that companies can bring forth to meet the stated AoIs. All details of the process shall be governed by this CSO unless otherwise noted or expanded upon in each AoI. Complete CSO details are contained in the attached document "FY22 DAF ACT COVID-19 Commercial Solutions Offering (CSO)" below. Interested parties should continue to monitor this Notice for updated information and publication of specific AoIs. UPDATED 02 NOV 2021: CSO FA8101-22-S-C001 is updated by amendment to publish the following Areas of Interest (AoI): AoI-0001 DOMESTIC INDUSTRIAL BASE EXPANSION OF ACRYLONITRILE BUTADIENE RUBBER (NBR) for NITRILE MEDICAL GLOVES_Closes 23 November 2021 at 4:00pm CST. AoI-0002 DOMESTIC INDUSTRIAL BASE EXPANSION OF KEY CHEMICALS FOR ACRYLONITRILE_Closes 23 November 2021 at 4:00pm CST. AoI-0003 N95 RESPIRATOR INDUSTRIAL BASE CAPACITY PRESERVATION_Closes 23 November 2021 at 4:00pm CST. UPDATED 03 NOV 2021: CSO FA8101-22-S-C001 is updated by amendment to publish the following Area of Interest (AoI): AoI-0004 Domestic Industrial Base Expansion of Isolation and Surgical (L2/L3/L4) Disposable Gowns Manufacturing and Medical Grade Man-Made Fibers for Production UPDATED 08 NOV 2021: CSO FA8101-22-S-C001 is updated by amendment to publish updated Area of Interest (AoI) which contain a due date of 12 November 2021at 04:00 PM CST for AoI question submission. UPDATED 16 NOV 2021: CSO FA8101-22-S-C001 is updated by amendment to publish the Questions and Answers in response to the CSO and AoI's. The CSO document has also been amended to correct a typographical error. The aforementioned amendments do not change the due dates outlined in any of the AoIs. UPDATED 17 NOV 2021: CSO FA8101-22-S-C001 is updated by amendment to publish updated AoI-0003 N95 RESPIRATOR INDUSTRIAL BASE CAPACITY PRESERVATION_REVISION to specificy/update the threshold and objective for ramp-up period. The aforementioned amendment does not change the due dates outlined within the AoI. UPDATED 23 NOV 2021: CSO FA8101-22-S-C001 is updated by amendment as follows: 1) AoI's 0001-0004 have been updated to extend the solution brief deadline(s) to 7 Dec 2021 and allow amendments to previously submitted solutions. 2) AoI-0003 N95 RESPIRATOR INDUSTRIAL BASE CAPACITY PRESERVATION has been amended to request additional information. 3) The Questions and Answers document has also been updated to change to make correct a typographical error and interchange the questions and answers from AoI-0003 and AoI-0004. UPDATED 3 DEC 2021: CSO FA8101-22-S-C001 is updated by amendment as follows: 1) AoI's 0001-0004 have been updated to add clarififying language to Paragraph 5.0 pertaining to the requirements of proposal amendments. Changes were highlighted for convenience. The aforementioned amendments do not change the due dates outlined in any of the AoIs. UPDATED 20 JAN 2022: CSO FA8101-22-S-C001 is updated by amendment as follows: 1) AoI 0003 N95 RESPIRATOR INDUSTRIAL BASE CAPACITY PRESERVATION has been revised to clarify the Government's requirement(s). Due to significant changes/updates, vendors may submit new solutions or revise previous solutions. This amendment effectively returns the AoI to Spiral 1 and is open to all qualified vendors, regardless of previous invitation or disposition to Spiral 2. Questions for this AoI amendment are due NLT 4:00pm CST, 21 January 2022. The deadline to submit solutions is 12:00 CST, 27 January 2022. UPDATED 24 JAN 2022: CSO FA8101-22-S-C001 is updated by amendment to publish the Questions and Answers in response to the AoI-0003 Amendment posted on 20 Jan 2022. This amendment does not effect the aforementioned submission deadline. UPDATED 10 FEB 2022: CSO FA8101-22-S-C001 is updated by amendment to delete references to Class Deviation 2018-O0016, section 879 of the National Defense Authorization Act (NDAA) for Fiscal Year (FY) 2017 and replace with Class Deviation 2022-O0007, section 803 of the NDAA for FY 2022. This update also removed FAR 52.223-99 in accordance with OSD(A&S)/DPC Memo dated 28 Dec 2021. These changes arey administrative in nature and have no further impact on the CSO or ongoing AoI's. UPDATED 18 APR 2022: Effective Immediately, CSO FA8101-22-S-C001 is updated by amendment to cancel AoI-0004 Domestic Industrial Base Expansion of Isolation of Isolation and Surgical (L2/L3/L4) Disposable Gowns Manufacturing and Medical Grade Man-Made Fibers for Production. As a result of this cancellation, all Spiral 2 activities will cease and no awards will be made for this AoI in Spiral 3. UPDATED 2 SEP 2022: Effective Immediately, CSO FA8101-22-S-C001 is updated by amendment as follows: AoI-0002 DOMESTIC INDUSTRIAL BASE EXPANSION OF KEY CHEMICALS FOR ACRYLONITRILE BUTADIENE RUBBER is amended to remove the requirement(s) for Butadiene and Dispersions. The aforementioned amendment(s) do not change the deadlines or submission dates previously outlined in the CSO or AoI. Note: Specific contract information/response address is located within each posted AoI.